EGF, epidermal growth factor, 1950

N. diseases: 774; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE As high glucose is able to induce the expression of epidermal growth factor (EGF), which is intimately related with tumor progression, the aim of this study was to evaluate whether curcumin could influence the high glucose-induced EGF/EGFR pathway and the biological activity of pancreatic cancer cells. 30542713 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation. 31292163 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE However, Epidermal Growth Factor (EGF) promotes tumor progression even with significant EGR1 upregulation. 30845713 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE Together, our findings indicate a complex mechanism underlying PGE<sub>2</sub>-induced EGF/EGFR signaling and transcriptional control, which plays a key role in cancer progression. 29599917 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE This phenomenon may be attributed to the cross talk between TGF-β signaling and other pathways, including EGF receptor (EGFR) signaling during cancer progression. 29215776 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Altogether, our studies reveal a crucial link of EGF receptor to NF-κB activation and tumor progression. 27991920 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation phenotype BEFREE Epidermal growth factor receptor (EGFR) and Cortactin are molecular markers that are important in tumour progression and development, and interact within the EGF pathway. 29201160 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. 28088463 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE These results suggest that HB-EGF secreted from KRas-mutated colorectal cancer cells promotes IMF migration through ERK and JNK activation, which, in turn, could support cancer progression. 28339087 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE TU-100 and some of its components and metabolites of these components inhibit tumor progression in two mouse models of colon cancer by blocking downstream pathways of EGF receptor activation. 27730672 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Therefore, our findings suggest that AQP3 is required for EGF-EGFR cell signaling in cancer cells and is a therapeutic target for cancer progression. 26896765 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE Supporting biological relevance, increased levels of EGF receptor during tumor progression were correlated with increased expression of the UPR gene signature. 26551735 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy. 25915843 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE Although EGFRvIII is constitutively active and promotes cancer progression, its activity is attenuated compared with EGF-ligated wild-type EGFR, suggesting that EGFRvIII may function together with other signaling receptors in cancer cells to induce an aggressive phenotype. 25347738 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation phenotype BEFREE Cripto, the founding member of the EGF-CFC genes, plays an essential role in embryo development and is involved in cancer progression. 25629528 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression. 24346967 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE However, there are limited data regarding the EGF-mediated signaling affecting functional cell properties and the expression of extracellular matrix macromolecules implicated in cancer progression. 24792576 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE The results suggest that proHB-EGF may play an important role in tumor progression. 23349913 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Epidermal growth factor (EGF) plays a critical role in malignant transformation of hepatocytes and tumor progression. 23419149 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation phenotype BEFREE Due to the interaction between HER2 and other ErbB receptors, HER2 is implicated in the EGF family of ligands-regulated tumor progression. 23542467 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in diverse cellular processes and as regulators of several microRNAs (miRNAs), thus contributing to tumor progression. 23650389 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation phenotype BEFREE MET, a receptor tyrosine kinase for hepatocyte growth factor, is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI). 21733594 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE Although HB-EGF is widely expressed in tumors when compared with normal tissue, its contribution to cancer progression remains obscure. 22209887 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE These results indicate that EGF may affect claudins and tight junctional functions in ovarian cancer cells during cancer progression. 22544349 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE While elevated expression of HB-EGF in cancer cells and its contribution to tumor progression are well documented, the effects of HB-EGF expression in the tumor stroma have not been clarified. 22009535 2011